DE69829483T2 - Testverfahren für Gq Protein gekoppelter Rezeptur-Agonisten und Antogonisten - Google Patents

Testverfahren für Gq Protein gekoppelter Rezeptur-Agonisten und Antogonisten Download PDF

Info

Publication number
DE69829483T2
DE69829483T2 DE69829483T DE69829483T DE69829483T2 DE 69829483 T2 DE69829483 T2 DE 69829483T2 DE 69829483 T DE69829483 T DE 69829483T DE 69829483 T DE69829483 T DE 69829483T DE 69829483 T2 DE69829483 T2 DE 69829483T2
Authority
DE
Germany
Prior art keywords
cells
hpth
hkrk
pth
pthr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69829483T
Other languages
German (de)
English (en)
Other versions
DE69829483D1 (de
Inventor
Richard F. BRINGHURST
Hisashi Takasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of DE69829483D1 publication Critical patent/DE69829483D1/de
Application granted granted Critical
Publication of DE69829483T2 publication Critical patent/DE69829483T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69829483T 1997-07-31 1998-07-30 Testverfahren für Gq Protein gekoppelter Rezeptur-Agonisten und Antogonisten Expired - Lifetime DE69829483T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US903977 1997-07-31
US08/903,977 US6183974B1 (en) 1997-07-31 1997-07-31 Screening assays for G protein coupled receptor agonists and antagonists
PCT/US1998/015877 WO1999006535A1 (en) 1997-07-31 1998-07-30 Screening assays for g protein coupled receptor agonists and antagonists

Publications (2)

Publication Number Publication Date
DE69829483D1 DE69829483D1 (de) 2005-04-28
DE69829483T2 true DE69829483T2 (de) 2006-04-27

Family

ID=25418329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69829483T Expired - Lifetime DE69829483T2 (de) 1997-07-31 1998-07-30 Testverfahren für Gq Protein gekoppelter Rezeptur-Agonisten und Antogonisten

Country Status (8)

Country Link
US (2) US6183974B1 (https=)
EP (1) EP1012241B1 (https=)
JP (1) JP4261766B2 (https=)
AT (1) ATE291615T1 (https=)
AU (1) AU8675098A (https=)
DE (1) DE69829483T2 (https=)
ES (1) ES2239398T3 (https=)
WO (1) WO1999006535A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4486256B2 (ja) * 1998-10-22 2010-06-23 ザ・ジェネラル・ホスピタル・コーポレイション 副甲状腺ホルモン（ＰＴＨ）および副甲状腺ホルモン関連ペプチド（ＰＴＨｒＰ）の生物活性ペプチドおよびペプチド誘導体
WO2001023521A2 (en) * 1999-09-29 2001-04-05 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2002339843B2 (en) * 2001-07-23 2007-12-06 The General Hospital Corporation Conformationally constrained parathyroid hormone (PTH) analogs
US7166463B2 (en) * 2001-11-16 2007-01-23 The Regents Of The University Of Colorado Nucleic acids encoding modified olfactory cyclic nucleotide gated ion channels
US7795220B2 (en) * 2003-03-19 2010-09-14 The General Hospital Corporation Conformationally constrained parathyroid hormones with alpha-helix stabilizers
JP4871128B2 (ja) * 2003-07-17 2012-02-08 ザ ジェネラル ホスピタル コーポレイション 高次構造的に制約された副甲状腺ホルモン（ｐｔｈ）アナログ
DOP2006000008A (es) * 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
US7833730B2 (en) * 2006-04-11 2010-11-16 Arena Pharmaceuticals, Inc. Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
WO2008019062A2 (en) * 2006-08-04 2008-02-14 The General Hospital Corporation Polypeptide derivatives of parathyroid hormone (pth)
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
CN104072606B (zh) * 2007-08-01 2017-09-22 总医院有限公司 利用g蛋白偶联受体和相关组合物的筛选方法
EP2108960A1 (en) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY
MX358161B (es) 2010-05-13 2018-08-06 The General Hospital Corp Star Analogos de hormona paratiroidea y usos para los mismos.
JP6093946B2 (ja) * 2014-02-25 2017-03-15 国立大学法人東北大学 Ｇタンパク質共役型受容体のシグナル伝達の検出方法
US11975050B2 (en) 2018-03-16 2024-05-07 The General Hospital Corporation Parathyroid hormone polypeptide conjugates and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462856A (en) 1990-07-19 1995-10-31 Bunsen Rush Laboratories, Inc. Methods for identifying chemicals that act as agonists or antagonists for receptors and other proteins involved in signal transduction via pathways that utilize G-proteins
DE69233472T2 (de) * 1991-04-05 2006-02-09 The General Hospital Corp., Charlestown Parathormonrezeptor und dafür codierende DNA
DE4138621A1 (de) 1991-11-25 1993-06-17 Boehringer Ingelheim Int Verfahren zum screenen von substanzen mit modulierender wirkung auf einen rezeptorabhaengigen zellulaeren signaluebertragungsweg

Also Published As

Publication number Publication date
AU8675098A (en) 1999-02-22
JP4261766B2 (ja) 2009-04-30
DE69829483D1 (de) 2005-04-28
US6183974B1 (en) 2001-02-06
US7033773B1 (en) 2006-04-25
ATE291615T1 (de) 2005-04-15
WO1999006535A1 (en) 1999-02-11
JP2001512664A (ja) 2001-08-28
EP1012241B1 (en) 2005-03-23
EP1012241A1 (en) 2000-06-28
ES2239398T3 (es) 2005-09-16
EP1012241A4 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
DE69829483T2 (de) Testverfahren für Gq Protein gekoppelter Rezeptur-Agonisten und Antogonisten
DE60018085T2 (de) Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden
DE69938064T2 (de) Aminoterminal modifizierte parathyroidhormon (pth) analoge
Cheloha et al. PTH receptor-1 signalling—mechanistic insights and therapeutic prospects
DE69734157T2 (de) Parathyroidhormon-verwandthe peptidanaloge
Holmes et al. Magnocellular axons in passage through the median eminence release vasopressin
Palazzi et al. Galanin reduces carbachol stimulation of phosphoinositide turnover in rat ventral hippocampus by lowering Ca2+ influx through voltage‐sensitive Ca2+ channels
Barrett et al. Role of calcium in angiotensin II-mediated aldosterone secretion
DE60013417T2 (de) Verfahren zum screenen von fxr-rezeptormodulatoren
DE60123635T2 (de) Methode und zusammensetzung zur förderung von osteogenese
Armstrong et al. Pulsatile and sustained gonadotropin-releasing hormone (GnRH) receptor signaling
Rochel et al. Carnosine release from olfactory bulb synaptosomes is calcium‐dependent and depolarization‐stimulated
Vollenweider et al. Effect of climbing fiber deprivation on release of endogenous aspartate, glutamate, and homocysteate in slices of rat cerebellar hemispheres and vermis
DE69832206T2 (de) Pth rezeptor und testverfahren unter verwendung desselben
TEITELBAUM et al. Coupling of the canine renal parathyroid hormone receptor to adenylate cyclase: modulation by guanyl nucleotides and iV-ethylmaleimide
DE69936451T2 (de) Verwendung von anti-prolaktin agentien zur behandlung von krebs
DE60033576T2 (de) Methoden zum screening knochenmorphogenetishemimetika
DE102005051789A1 (de) Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
Kourie Synthetic mammalian C-type natriuretic peptide forms large cation channels
Spurney et al. Aluminum is a weak agonist for the calcium-sensing receptor
Eckland et al. Immunoreactive vasopressin and oxytocin in hypothalamo-hypophysial portal blood of the Brattleboro and Long–Evans rat: effect of adrenalectomy and dexamethasone
Tsuda et al. Modulation of [3H] dopamine release by neuropeptide Y in rat striatal slices
Regunathan et al. Specific binding of inositol hexakisphosphate (phytic acid) to adrenal chromaffin cell membranes and effects on calcium-dependent catecholamine release
DE69330695T2 (de) Abtrennung und Charakterisierung des Wachstumshormon-Releasing-Hormon-Rezeptors
Priestley The effect of baclofen and somatostatin on neuronal activity in the rat ventromedial hypothalamic nucleus in vitro

Legal Events

Date Code Title Description
8364 No opposition during term of opposition